Major Adverse Cardiac Events (MACE)
Showing 1 - 25 of >10,000
The Occurrence of MACE in AMI Receiving Pitavastatin/Valsartan
Recruiting
- Hypercholesterolemia
- Pitavastatin 4mg
-
Seoul, Seocho-gu, Korea, Republic ofJWP
Apr 11, 2021
Obesity Trial (Naltrexone-Bupropion (NB) Combination, Placebo)
Not yet recruiting
- Obesity
- Naltrexone-Bupropion (NB) Combination
- Placebo
- (no location specified)
Oct 18, 2023
Anticoagulant Drug Intervention on Postoperative MALE and MACE
Recruiting
- Anticoagulant Drugs
- +2 more
- anticoagulant or antiplatelet drugs
-
Hangzhou, None Selected, ChinaFirst Affiliated Hospital of Zhejiang University
May 8, 2023
Diabetes, Type 2, Major Adverse Cardiac Events Trial in Hangzhou (CGM)
Not yet recruiting
- Diabetes Mellitus, Type 2
- Major Adverse Cardiac Events
- CGM
-
Hangzhou, Chinathe Second Affiliated Hospital Zhejiang University Schoolof Medi
Sep 23, 2023
Novel Cardiovascular Biomarkers in Patients With Kidney Disease
Not yet recruiting
- Haemodialysis Complication
- Major Adverse Cardiac Events
- Cardiac Biomarkers
- +2 more
- (no location specified)
Sep 14, 2023
Cardiovascular Primary Prevention Strategy Trial in Murray (Coronary Artery Calcium Screening and Statin Treatment, Standard
Recruiting
- Cardiovascular Primary Prevention Strategy
- Coronary Artery Calcium Screening and Statin Treatment
- Standard Treatment
-
Murray, UtahIntermountain Medical Center and Intermountain Clinics
Aug 8, 2022
Inclisiran on Major Adverse Cardiovascular Events in French
Not yet recruiting
- Atherosclerotic Cardiovascular Disease
- Inclisiran sodium
- +3 more
- (no location specified)
Jul 26, 2023
Noncardiac Surgery Trial in Guangzhou (Perioperative cardiac biomarker measurement)
Recruiting
- Noncardiac Surgery
- Perioperative cardiac biomarker measurement
-
Guangzhou, Guangdong, ChinaNanfang Hospital, Southern Medical University
Apr 2, 2023
MACE and PE in Elective Primary TKA & THA
Completed
- Cardiovascular Complication
- +4 more
-
Larissa, GreeceUniversity of Thessaly
Oct 29, 2021
Characterization of Arrhythmia-induced Cardiomyopathy
Recruiting
- Cardiomyopathy
- Arrhythmia-induced Cardiomyopathy (AiCM)
- Data collection: Major adverse cardiovascular event (MACE) assessment questionnaire (prospective part)
- +3 more
-
Basel, SwitzerlandUniversity Hospital Basel, Department of Cardiology
Jan 2, 2023
Cardiac Tumor and Risk Stratification of Subsequent Adverse
Not yet recruiting
- Cardiac Tumor
-
Xi'an, Shaanxi, ChinaFirst Affiliated Hospital of Xi'an Jiantong University
Oct 19, 2023
Adverse Events in Acute Limb Ischemic Patient Undergoing
Recruiting
- Major Adverse Cardiac Events
- Adverse Effect of Unspecified General Anesthetic
-
Bangkok, Thailand
- +1 more
May 3, 2022
Washington Hospital Center With Drug Eluting Stents - Synergy
Active, not recruiting
- Incidence of Major Adverse Cardiac Events
- PCI with Synergy Stent
-
Washington, District of ColumbiaMedStar Washington Hospital Center
Jan 3, 2022
Cardiac Disease Trial in San Donato Milanese (Cerebral autoregulation monitoring)
Not yet recruiting
- Cardiac Disease
- Cerebral autoregulation monitoring
-
San Donato Milanese, Milan, ItalyVlasta Bari
Mar 15, 2023
Major Adverse Cardiovascular Events in Coronary Artery Disease
Completed
- Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease
-
Jinan, Shandong, ChinaYuguo Chen
Sep 20, 2022
Arteriosclerosis, Hypercholesterolaemia Trial (MK-0616, Placebo)
Not yet recruiting
- Arteriosclerosis
- Hypercholesterolaemia
- MK-0616
- Placebo
- (no location specified)
Aug 17, 2023
Coronary Artery Disease Trial in United States (Colchicine, Placebo)
Not yet recruiting
- Coronary Artery Disease
- Colchicine
- Placebo
-
Long Beach, California
- +4 more
Nov 15, 2022
Atrial Fibrillation, Anticoagulant Adverse Reaction, Stroke Trial (low-dose rivaroxaban, Standard-dose rivaroxaban)
Not yet recruiting
- Atrial Fibrillation
- +3 more
- low-dose rivaroxaban
- Standard-dose rivaroxaban
- (no location specified)
Oct 25, 2023
Primary Prevention of Atherosclerotic Cardiovascular Disease Trial (Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran)
Not yet recruiting
- Primary Prevention of Atherosclerotic Cardiovascular Disease
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Placebo in 1.5ml
- (no location specified)
Feb 13, 2023
Acute Kidney Injury, Septic Shock, Nicotinamide Trial in Amiens (Nicotinamide treatment, treatment)
Recruiting
- Acute Kidney Injury
- +3 more
- Nicotinamide treatment
- placebo treatment
-
Amiens, FranceCHU Amiens
Dec 8, 2022
Adverse Events in Pediatric Cardiac Surgery
Completed
- Congenital Heart Disease in Children
- +2 more
- Fluid balance
-
Brussels, BelgiumHôpital Universitaire des Enfants Reine Fabiola
Jul 19, 2022
Endothelial Dysfunction and Non-cardiac Surgery
Recruiting
- Surgery
- +3 more
- FMD - Troponin measurement
-
Independencia, Santiago, ChileHospital Clínico de la Universidad de Chile
Mar 25, 2023
Major Adverse Cardiovascular Events for Naldemedine and Other
Recruiting
- Opioid-induced Constipation
- Naldemedine
- +2 more
-
Wilmington, DelawareResearch Site
Feb 28, 2022
Statin Dose Trial in Shiraz (moderate statin dose, high dose statin)
Completed
- Statin Dose
- moderate statin dose
- high dose statin
-
Shiraz, Outside Of The US, Iran, Islamic Republic ofProfessor kojuri cardiology clinic
Jun 10, 2021